These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32346890)

  • 1. Precision dosing-based optimisation of paroxetine during pregnancy for poor and ultrarapid CYP2D6 metabolisers: a virtual clinical trial pharmacokinetics study.
    Almurjan A; Macfarlane H; Badhan RKS
    J Pharm Pharmacol; 2020 Aug; 72(8):1049-1060. PubMed ID: 32346890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems.
    Chen R; Wang H; Shi J; Shen K; Hu P
    Eur J Clin Pharmacol; 2015 Jul; 71(7):835-41. PubMed ID: 25967538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision dosing of venlafaxine during pregnancy: a pharmacokinetics modelling approach.
    Alenezi M; Badhan RKS
    J Pharm Pharmacol; 2024 Jan; 76(2):122-137. PubMed ID: 38142123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine.
    Charlier C; Broly F; Lhermitte M; Pinto E; Ansseau M; Plomteux G
    Ther Drug Monit; 2003 Dec; 25(6):738-42. PubMed ID: 14639062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of the cytochrome P450 2D6 *10/*10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis.
    Nishimura M; Ueda M; Saruwatari J; Nakashima H; Ogusu N; Aoki A; Tsuchimine S; Matsuda K; Iwashita K; Ono T; Oniki K; Shimoda K; Yasui-Furukori N
    Pharmacogenet Genomics; 2016 Sep; 26(9):403-13. PubMed ID: 27187662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The application of precision dosing in the use of sertraline throughout pregnancy for poor and ultrarapid metabolizer CYP 2C19 subjects: A virtual clinical trial pharmacokinetics study.
    Almurjan A; Macfarlane H; Badhan RKS
    Biopharm Drug Dispos; 2021 Jun; 42(6):252-262. PubMed ID: 33851424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine.
    Sawamura K; Suzuki Y; Someya T
    Eur J Clin Pharmacol; 2004 Oct; 60(8):553-7. PubMed ID: 15349705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimising Fluvoxamine Maternal/Fetal Exposure during Gestation: A Pharmacokinetic Virtual Clinical Trials Study.
    Burhanuddin K; Badhan R
    Metabolites; 2022 Dec; 12(12):. PubMed ID: 36557319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects.
    Yoon YR; Cha IJ; Shon JH; Kim KA; Cha YN; Jang IJ; Park CW; Shin SG; Flockhart DA; Shin JG
    Clin Pharmacol Ther; 2000 May; 67(5):567-76. PubMed ID: 10824636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects.
    Yasui-Furukori N; Saito M; Inoue Y; Niioka T; Sato Y; Tsuchimine S; Kaneko S
    Eur J Clin Pharmacol; 2007 Jan; 63(1):51-6. PubMed ID: 17124578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.
    Kuhn UD; Kirsch M; Merkel U; Eberhardt AM; Wenda B; Maurer I; Härtter S; Hiemke C; Volz HP; Balogh A
    Int J Clin Pharmacol Ther; 2007 Jan; 45(1):36-46. PubMed ID: 17256449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.
    Skinner MH; Kuan HY; Pan A; Sathirakul K; Knadler MP; Gonzales CR; Yeo KP; Reddy S; Lim M; Ayan-Oshodi M; Wise SD
    Clin Pharmacol Ther; 2003 Mar; 73(3):170-7. PubMed ID: 12621382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.
    Lam YW; Gaedigk A; Ereshefsky L; Alfaro CL; Simpson J
    Pharmacotherapy; 2002 Aug; 22(8):1001-6. PubMed ID: 12173784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine Exposure.
    Badaoui S; Hopkins AM; Rodrigues AD; Miners JO; Sorich MJ; Rowland A
    AAPS J; 2021 Jan; 23(1):15. PubMed ID: 33404848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
    Stearns V; Johnson MD; Rae JM; Morocho A; Novielli A; Bhargava P; Hayes DF; Desta Z; Flockhart DA
    J Natl Cancer Inst; 2003 Dec; 95(23):1758-64. PubMed ID: 14652237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphism in CYP2D6 affects the pharmacokinetics and dose escalation of paroxetine controlled-release tablet in healthy Chinese subjects.
    Chen R; Shen K; Hu P
    Int J Clin Pharmacol Ther; 2017 Nov; 55(11):853-860. PubMed ID: 28933337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy.
    Ververs FF; Voorbij HA; Zwarts P; Belitser SV; Egberts TC; Visser GH; Schobben AF
    Clin Pharmacokinet; 2009; 48(10):677-83. PubMed ID: 19743889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.
    Segura M; Farré M; Pichini S; Peiró AM; Roset PN; Ramírez A; Ortuño J; Pacifici R; Zuccaro P; Segura J; de la Torre R
    Clin Pharmacokinet; 2005; 44(6):649-60. PubMed ID: 15910012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia.
    Stedman CA; Begg EJ; Kennedy MA; Roberts R; Wilkinson TJ
    Hum Psychopharmacol; 2002 Jun; 17(4):187-90. PubMed ID: 12404686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.